Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Aiforia Technologies Plc, Company release, September 25, 2024, 09:00 a.m. EEST
The Board of Directors of Aiforia Technologies Plc has decided on a new option rights plan
The Board of Directors of Aiforia Technologies Plc ("Aiforia") has decided on September 24, 2024, to launch a new option rights plan 2024 on the terms set out below and to extend the subscription period of the old option rights plans 2016–2021 by three years until the end of 2028. There is a weighty financial reason for Aiforia to issue option rights as the option rights are intended to form a part of the Aiforia's incentive and commitment program for members of the management team of the company, key personnel of the company and its subsidiaries as well as other persons fundamental to the company and its subsidiaries.
Option rights plan 2024
Based on the authorization granted by the Annual General Meeting held on April 4, 2024, the Board of Directors of Aiforia has resolved to grant a maximum of 400,000 option rights entitling to shares to certain members of the management team under the option rights plan 2024. The option rights will be offered without consideration. Each option right entitles to subscribe for one ordinary share in Aiforia for a subscription price of EUR 3.94 per share (volume-weighted average share price during H1/2024 review period).
The subscription period for the option rights granted on the basis of the option program 2024 starts on December 31, 2026, and ends on December 31, 2030.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358 40 500 9878
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com